RCM
CMPX icon

RA Capital Management’s Compass Therapeutics CMPX Stock Holding History

RA Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-532,958
Closed -$730K – 90
2022
Q1 		$730K Sell
532,958
-1,316,560
-71% -$2.72M 0.02% 96
2021
Q4 		$5.86M Buy
+1,849,518
New +$6.13M 0.1% 92

Other funds holding CMPX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

RA Capital Management's CMPX Position: Q2 2022 in Review

RA Capital Management sold out of Compass Therapeutics (CMPX) in Q2 2022, closing a stake of 532,958 shares — an estimated $730K sold.

RA Capital Management first reported a position in CMPX in Q4 2021 and held it in 2 quarters. The position peaked at $5.86M in Q4 2021. 34 funds tracked by Wall St. Rank hold CMPX as of Q2 2022.

  • RA Capital Management reported no remaining Compass Therapeutics position as of Q2 2022 after selling out during the quarter.
  • RA Capital Management sold 532,958 Compass Therapeutics shares in Q2 2022, an estimated $730K.
  • RA Capital Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 2 quarters.
  • RA Capital Management's Compass Therapeutics position peaked at $5.86M in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.